.
MergerLinks Header Logo

New Deal


Announced

Completed

Calyxt completed the merger with Cibus.

Financials

Edit Data
Transaction Value-
Consideration TypeOrdinary Shares
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Acquisition

Domestic

Biotechnology

Friendly

United States

biotechnology research

Majority

Private

Completed

Synopsis

Edit

Calyxt, a plant-based synthetic biology company, completed the merger with Cibus, an agricultural technology company that develops, and licenses gene edited plant traits to seed companies. Financial terms were not disclosed. "We are excited to combine our joint wealth of experience that consolidates landmark intellectual property in agricultural gene editing including Transcription Activator-like Effector Nucleases and Oligonucleotide Directed Mutagenesis. The merger of two of the original pioneers in what has become the field of gene editing in agriculture, will enable new and expanded partnerships and opportunities to make farming more productive and to create a new generation of sustainable ingredients that are renewable and low-carbon," Greg Gocal, Cibus Co-Founder, Executive Vice President and Chief Scientific Officer.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US